Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Top Drugs To Watch At ASH 2017: CAR-T, Venetoclax Among Highlights

Executive Summary

Highlights of the upcoming American Society of Hematology meeting include updated data for CAR-T therapies, pivotal results moving major brands into bigger markets, PD-1 inhibitors branching out into new types of hematological malignancies and dueling gene therapies in hemophilia.


Related Content

Accelerated Development On The Cards In EU and US For Bluebird, Celgene’s CAR-T Therapy
CAR-T To Go: Juno Sees JCAR017 As Safer, Suited For Outpatients
Bluebird Bio Sings Cheerily Of Its "Biggest ASH Ever"
Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah
Caterpillar To Butterfly? Ablynx Says Caplacizumab Data Transformational
MURANO To Drive AbbVie/Roche's Venetoclax In CLL
A Cellectis Trial Death Points To Challenges Ahead For CAR-T
Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval
ALCYONE Paves Way For J&J/Genmab's Darzalex In Frontline Myeloma
Cellectis Moves First Off-The-Shelf CAR-T Into US Clinical Trials


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts